Anebulo Pharmaceuticals, Inc.

ANEB · NASDAQ
Analyze with AI
6/30/2025
6/30/2024
6/30/2023
6/30/2022
Operating Activities
Net Income-$8,485-$8,202-$11,732-$6,826
Dep. & Amort.$382$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$1,447$0$885$0
Change in WC$306-$799$1,164$908
Other Non-Cash$0$910$0$481
Operating Cash Flow-$6,350-$8,091-$9,683-$5,437
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$14,883-$62$6,647$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0-$265$0
Financing Cash Flow$14,883-$62$6,382$0
Forex Effect$0$0$0$0
Net Chg. in Cash$8,534-$8,153-$3,301-$5,437
Supplemental Information
Beg. Cash$3,094$11,247$14,548$19,986
End Cash$11,628$3,094$11,247$14,548
Free Cash Flow-$6,350-$8,091-$9,683-$5,437
Anebulo Pharmaceuticals, Inc. (ANEB) Financial Statements & Key Stats | AlphaPilot